EMA Application withdrawn: Orplatna (satraplatin) — Pharmion Ltd.

View source ↗

Summary

The EMA withdrew the application for Orplatna (satraplatin) from Pharmion Ltd., with the therapeutic area listed as prostatic neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostatic Neoplasms

Drugs mentioned

• Orplatna (satraplatin)

Snippet

Status: Application withdrawn. Therapeutic area: Prostatic Neoplasms. MAH: Pharmion Ltd.. Decision date: 31/12/2009